By the way, Effexor is not exactly a great drug either.
Just check my blog on
the topic and read about its side
and disastrous record when it comes to attempting to get off it.
But let me get back to what matters. The new drug provides a lucrative new revenue stream for
Wyeth. How lucrative? Well, on the day it won FDA approval (February 29) Wyeth stock soared 2.5% while the rest of Wall St tumbled 315 points. Did I men
tion any benefits to patients? I would, if I could think of any.